Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells

Journal of Clinical Immunology

Volumn 32, Issue 5, 2012, Pages 1071-1081

  Nagato, Kaoru ^a   Motohashi, Shinichiro ^a   Ishibashi, Fumihiro ^a   Okita, Kohsuke ^a   Yamasaki, Kazuki ^a   Moriya, Yasumitsu ^a   Hoshino, Hidehisa ^a   Yoshida, Shigetoshi ^c   Hanaoka, Hideki ^a   Fujii, Shin Ichiro ^b   Taniguchi, Masaru ^b   Yoshino, Ichiro ^a   Nakayama, Toshinori ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Institute of Physical and Chemical Research   (Japan)

^c RIKEN Research Center for Allergy and Immunology ^*

Author keywords

Antigen presenting cell; Immunotherapy; Invariant NKTcell; Non small cell lung cancer; Tumor infiltrating lymphocyte

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; GAMMA INTERFERON;

ADULT; ADVANCED CANCER; AGED; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL COUNT; CELL INFILTRATION; CELL METABOLISM; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPLORATORY RESEARCH; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM SURVIVAL; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT;

ADENOCARCINOMA; AGED; ANTIGEN-PRESENTING CELLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; GALACTOSYLCERAMIDES; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; LYMPH NODES; MALE; NATURAL KILLER T-CELLS; RECEPTORS, ANTIGEN, T-CELL; TUMOR MICROENVIRONMENT;

EID: 84866734196     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9697-9     Document Type: Article

References (33)

1. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR-mediated activation of Va14 NKT cells by glycosylceramides. Science. 1997; 278:1626-9.
2. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, et al. CD1d-mediated recognition of an a-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med. 1998; 188:1521-8.
3. Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med. 1998; 188:1529-34.
4. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, et al. Loss of IFN-y production by invariant NK T cells in advanced cancer. J Immunol. 2001; 167:4046-50.
5. Motohashi S, Kobayashi S, Ito T, Magara KK, Mikuni O, Kamada N, et al. Preserved IFN-y production of circulating Va24 NKT cells in primary lung cancer patients. Int J Cancer. 2002; 102:159-65.
6. + NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer. 2005; 116:87-93.
7. van der Vliet HJ, Nishi N, Koezuka Y, von Blomberg BM, van den Eertwegh AJ, Porcelli SA, et al. Potent expansion of human natural killer T cells using a-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J Immunol Methods. 2001; 247:61-72.
8. Yanagisawa K, Seino K, Ishikawa Y, Nozue M, Todoroki T, Fukao K. Impaired proliferative response of Va24 NKT cells from cancer patients against a-galactosylceramide. J Immunol. 2002; 168:6494-9.
9. Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii S, Dhodapkar KM, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med. 2003; 197:1667-76.
10. Molling JW, Langius JA, Langendijk JA, Leemans CR, Bontkes HJ, van der Vliet HJ, et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol. 2007; 25:862-8.
11. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, et al. A phase I study of a-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2005; 11:1910-7.
12. Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2006; 12:6079-86.
13. Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, et al. A phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol. 2009; 182:2492-501.
14. Motohashi S, Nakayama T. Invariant natural killer T cell-based immunotherapy for cancer. Immunotherapy. 2009; 1:73-82.
15. + natural killer T-cell activation by α-galactosylceramide. Int J Cancer. 2005; 117:265-73.
16. Grabenbauer GG, Lahmer G, Distel L, Niedobitek G. Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res. 2006; 12:3355-60.
17. van Beek J, zur Hausen A, Snel SN, Berkhof J, Kranenbarg EK, van de Velde CJ, et al. Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. Am J Surg Pathol. 2006; 30:59-65.
18. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 2001; 61:3932-6.
19. + T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res. 2003; 63:1555-9.
20. Menon AG, Janssen-van Rhijn CM, Morreau H, Putter H, Tollenaar RA, van de Velde CJ, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest. 2004; 84:493-501.
21. + tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol. 2004; 35:808-16.
22. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348:203-13.
23. Ryschich E, Notzel T, Hinz U, Autschbach F, Ferguson J, Simon I, et al. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res. 2005; 11:498-504.
24. + tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102:18538-43.
25. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10:942-9.
26. Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005; 11:1467-73.
27. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intra-tumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007; 25:2586-93.
28. Tachibana T, Onodera H, Tsuruyama T, Mori A, Nagayama S, Hiai H, et al. Increased intratumor Vα24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res. 2005; 11:7322-7.
29. Sawabata N, Miyaoka E, Asamura H, Nakanishi Y, Eguchi K, Mori M, et al. Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol. 2011; 6:1229-35.
30. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004; 350:351-60.
31. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005; 352:2589-97.
32. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006; 7:719-27.
33. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26:3552-9.